Compare Adaptive Biotechnologies Corp (ADPT) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Hershey Co — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Hershey Co trades at $184.11 (market cap $36.56B). The key difference: Hershey Co is far larger — about 9× Adaptive Biotechnologies Corp's market cap, and Hershey Co pays a 3.19% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HSY | |
|---|---|---|
Market Cap | $4.04B | $36.56B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $236.28 |
52-Week Low | $12.30 | $162.31 |
Enterprise Value | $4.10B | $41.70B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Hershey (HSY) trades at $183.19, up 0.24% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates by 33% and revenue growth of 4.5-5% guidance. Recent earnings show significant margin recovery to 45.3% as cocoa prices decline, supporting the stock's premium valuation at 24.86 P/E. Analyst consensus price target of $196.78 suggests 7.4% upside potential from current levels.
HSY presents a compelling investment case with improving fundamentals, dividend growth resumption, and margin expansion. However, risks include volume declines in salty snacks, competitive pressures, and potential cocoa price volatility. The stock's current technical overbought condition near resistance at $184 warrants caution despite positive earnings momentum and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
